Provider of real-time CRISPR gene editing analysis. It offers solutions for measuring RNP formation, DNA target binding, and cleavage activity. The platform enables researchers to optimize gRNA design, improve CRISPR efficiency, and accelerate breakthroughs in gene editing workflows. This allows for early detection of issues, reducing troubleshooting time and maximizing resource utilization. The company was founded in 2021 and headquartered in San Diego, United States. It has raised $12.5M in series a funding, with backing from Serra Ventures, Xcellerant Ventures, EvoNexus, BioBrit, and others. The company operates in the Life Sciences - Genomics space. The company leverages advanced technology to deliver innovative solutions tailored to its target market, addressing key industry challenges and driving value for its customers.
← All startups
CRISPR QC
Series AProvider of real-time CRISPR gene editing analysis. It offers solutions for measuring RNP formation, DNA target binding, and cleavage activity. The platform enables researchers to optimize gRNA design, improve CRISPR efficiency, and accelerate breakthroughs in gene editing workflows. This allows for early detection of issues, reducing troubleshooting time and maximizing resource utilization. The company was founded…
About
Business model
Genomics > Enabling Technologies > Technology Platforms > Gene Editing
Institutional investors
Serra VenturesXcellerant VenturesEvoNexusBioBritSUNCOAST VENTURES
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.